Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year
Novel illumination system with key components molded in Radel® PPSU for durability and repeated sterilization
Q3 FY25 revenue up 24% to Rs 3,230 crore
PAT after MI is Rs. 41 crore which is 162% increase
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
The Emcure Research Centre (ERC) will drive research across multiple dosage forms, including OSD, injectables, novel drug delivery systems (NDDS), inhalers and topical and transdermal formulations
The launch of Chlorpromazine Hydrochloride for Injection is the latest in a series of recent product launches from Piramal Critical Care
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines
Subscribe To Our Newsletter & Stay Updated
